SLS - SELLAS Life Sciences announces $4M registered direct offering priced at-the-market under Nasdaq rules
2023-10-31 08:53:38 ET
More on SELLAS Life Sciences
- Sellas Life Sciences stock jumps on FDA fast track designation for PTCL treatment
- SELLAS gains on FDA orphan drug status for its SLS009
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Historical earnings data for SELLAS Life Sciences
- Financial information for SELLAS Life Sciences
For further details see:
SELLAS Life Sciences announces $4M registered direct offering priced at-the-market under Nasdaq rules